Robert Shawah
Co-Founder & CFO at Acurx Pharmaceuticals
Research and development expenses for the three months ended 12/31/2024 were $800,000 compared to $1,900,000 for the three months ended 12/31/2023, a decrease of $1,100,000 The decrease was primarily due to a decrease in consulting related costs of $1,200,000 offset by an increase in manufacturing costs of $100,000 For the year ended 12/31/2024, research and development expenses were $5,400,000 compared to $6,000,000 for the year ended 12/31/2023, a decrease of $600,000 The decrease was primarily due to $1,600,000 decrease in consulting related costs, offset by a $1,000,000 increase in manufacturing related costs. General and administrative expenses for the three months ended 12/31/2024, were $2,000,000 compared to $3,200,000 for the three months ended 12/31/2023, a decrease of $1,200,000 The decrease is primarily due to $500,000 decrease in professional fees, a $500,000 decrease in share based compensation costs and a $200,000 decrease in employee compensation costs. For the year ended 12/31/2024, general and administrative expenses were $8,700,000 compared to $8,500,000 for the year ended 12/31/2023, an increase of $200,000 The increase is primarily due to a $700,000 increase in professional fees, a $300,000 increase in legal fees, offset by a $600,000 decrease in share based compensation costs and a $200,000 decrease in insurance costs.